Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaloacetate in Myasthenia Gravis
NCT04965987Phase 1Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in myasthenia gravis (MG) comparing Oxaloacetate with Placebo (2 arms). Primary endpoint: Frequency and Severity of Adverse Events at 12 weeks. Planned start Aug 2025; status: withdrawn.
02
Drugs
oxaloacetate
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04965987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965987.